Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310305 | 0.88 | TACR1 (0.44) | TACR1ALDH1A1MAPTHPGD | |
| SCHEMBL3821496 | 0.85 | TACR1 (0.37) | TACR1 | |
| SCHEMBL8706262 | 0.84 | TACR1 (0.37) | TACR1NOTUMALDH1A1HSP90AA1MAPT | |
| SCHEMBL4203119 | 0.84 | TACR1 (0.43) | TACR1 | |
| SCHEMBL7193387 | 0.83 | TACR1 (0.41) | TACR1 | |
| SCHEMBL5815553 | 0.83 | TACR1 (0.44) | TACR1 | |
| SCHEMBL8322001 | 0.82 | TACR1 (0.38) | TACR1MAPT | |
| SCHEMBL6580528 | 0.82 | TACR1 (0.41) | TACR1 | |
| SCHEMBL6541742 | 0.82 | PTGDR2 (0.48) | TACR1 | |
| SCHEMBL7193383 | 0.82 | TACR1 (0.40) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006115286-A1 | PIPERIDINE DERIVATIVES, CRYSTAL, PROCESS FOR PRODUCING THE SAME, AND USE AS TACHIKININ RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241145-A1 | Piperidine derivative crystal, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241145-A1 | Piperidine derivative crystal, process for producing the same, and use | PKD2, PKD1, TACR1 | TACR1 3/4885NOTUM 1415/4885SCN5A 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.